• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Recombinant Zoster Vaccine Uptake and Risk of Flares Among Older Adults with Immune-Mediated Inflammatory Diseases in the United States
CONCLUSIONS: We did not find an increase in presumed flares following RZV vaccination. Among adults aged ≥50 years with IMIDs, a substantial proportion received RZV compared to general zoster coverage estimates and series-completion was high. This article is protected by copyright. All rights reserved.PMID:35666070 | DOI:10.1002/art.42261
Source: Herpes - June 6, 2022 Category: Infectious Diseases Authors: Jessica Leung Tara C Anderson Kathleen Dooling Fenglong Xie Jeffrey R Curtis Source Type: research

Projected risks and health benefits of vaccination against herpes zoster and related complications in US adults
Hum Vaccin Immunother. 2022 Apr 27:1-5. doi: 10.1080/21645515.2022.2060668. Online ahead of print.ABSTRACTThe Advisory Committee on Immunization Practices (ACIP) recommends recombinant zoster vaccine (RZV) to prevent against herpes zoster (HZ) and related complications in immunocompetent adults ≥50 y and immunocompromised adults ≥19 y. In 2019, a statistical safety signal for Guillain-Barré syndrome (GBS) following RZV was identified using data from the Vaccine Safety Datalink (VSD). Subsequently, the U.S. Food and Drug Administration (FDA), the Centers for Disease Control and Prevention (CDC), and collaborators under...
Source: Herpes - April 27, 2022 Category: Infectious Diseases Authors: Cara B Janusz Tara C Anderson Andrew J Leidner Grace M Lee Kathleen Dooling Lisa A Prosser Source Type: research

Factors influencing series completion rates of recombinant herpes zoster vaccine in the United States: A retrospective pharmacy and medical claims analysis
CONCLUSION: Pharmacists contribute substantially to the overall high RZV completion rates in the United States. However, completion rates can be improved, especially in people receiving their first RZV dose at a physician's office. Future strategies should aim at lowering barriers to completing vaccination series in African Americans, Medicaid beneficiaries, and people with comorbidities.PMID:34893442 | DOI:10.1016/j.japh.2021.11.010
Source: Herpes - December 11, 2021 Category: Infectious Diseases Authors: Brandon J Patterson Chi-Chang Chen Catherine B McGuiness Siyu Ma Lisa I Glasser Kainan Sun Philip O Buck Source Type: research

Risk of Guillain-Barre syndrome following herpes zoster, United States, 2010-2018
This study provides new and methodologically rigorous epidemiologic support for an association between HZ and GBS, and useful context regarding the benefits versus potential risks of zoster vaccination.PMID:34856864 | DOI:10.1080/21645515.2021.1985890
Source: Herpes - December 3, 2021 Category: Infectious Diseases Authors: Tara C Anderson Jessica W Leung Rafael Harpaz Kathleen L Dooling Source Type: research